7results about How to "Reduce peroxidation" patented technology

The invention discloses an application of a PpWRKY53 transcription factor in improving heat resistance of Chinese pear fruits, the transcription factor is a positive regulatory factor of Chinese pears responding to high temperature stress, overexpression of the transcription factor PpWRKY53 gene in the Chinese pear fruits can significantly reduce hydrogen peroxide accumulation and membrane lipid peroxidation caused by high temperature, effectively alleviate water stain type browning symptoms of the fruits, and improve the heat resistance of the Chinese pears. The fruit hardness is improved. The invention provides a key gene resource for creating new germplasm of heat-resistant Chinese pears and breeding new varieties with high-temperature-resistant characteristics, and has important scientific and application values for ensuring stable production of summer Chinese pear industry and improving fruit quality and economic benefits.

The invention discloses procyanidine B2G2 from purple sweet potato Ningzi No.4 and application thereof, and belongs to the technical field of biological medicine, the molecular formula of the procyanidine B2G2 is C44H34O20, and the molecular weight of the procyanidine B2G2 is 882.736 Da. The procyanidine B2G2 remarkably relieves acute lung injury ALI by inhibiting inflammatory response and ferroptosis induced by klebsiella pneumoniae KP; experiments show that B2G2 can reduce the lung tissue injury score, the lung wet / dry ratio, the expression of inflammatory factors TNF-alpha, IL-6 and IL-1beta and the bacterial load, and up-regulate the expression of ferroptosis related proteins GPX4, SLC7A11 and HO-1; in addition, B2G2 is non-toxic to liver and kidney functions and has good safety, and the application provides a new drug candidate scheme for preparation of drugs for treating acute lung injury.

This invention relates to a skin-brightening composition containing *Tea laurentii* essential oil, its preparation method, and its application. The composition comprises the following components: *Tea laurentii* essential oil, ascorbic acid peptides, oat β-glucan, camellia seed oil, and tiger nut oil. The weight ratio of *Tea laurentii* essential oil, ascorbic acid peptides, oat β-glucan, camellia seed oil, and tiger nut oil is (0.1-10):(0.01-1):(0.01-5):(0.01-5):(0.01-5). The *Tea laurentii* essential oil is obtained by fermenting *Tea laurentii* tea leaves with *Aspergillus cristatus* followed by supercritical CO2 processing. 2 The composition obtained by extraction; the components of the present invention have synergistic effects, simultaneously blocking inflammatory roughness and dullness, breaking through the limitation of traditional products that only target dehydrated roughness, and providing a comprehensive solution for sensitive skin without hormone stimulation.

This invention belongs to the field of daily chemical products, specifically relating to a method for preparing hydrogenated castor seed oil and its skincare composition, comprising the following steps: S1. Crushing castor seeds and sieving them to obtain castor seed powder; S2. Treating the castor seed powder in a low-frequency pulsed electric field and intermittent microwave to obtain pretreated castor seed powder; S3. Mixing the pretreated castor seed powder with a compound enzyme preparation and performing subcritical extraction to obtain an extract; S4. Filtering the extract and distilling it to obtain a refined filtrate; S5. Mixing the refined filtrate with a palladium-on-carbon catalyst to obtain a semi-finished product; S6. Passing the semi-finished product through a fixed bed of activated carbon to obtain a primary filtrate, which is then filtered to obtain hydrogenated castor seed oil. The preparation method of this invention effectively retains the natural active ingredients in castor seed oil, thereby improving the effectiveness of the prepared hydrogenated castor seed oil, reducing organic solvent and heavy metal residues, and facilitating the application of hydrogenated castor seed oil in skincare compositions.

The application relates to an application of a traditional Chinese medicine composition in a drug for chronic obstructive pulmonary disease, characterized in that the traditional Chinese medicine composition comprises the following components in parts: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Amygdalus 1-100 parts, Notopterygium 1-100 parts, Zingiber officinale 1-100 parts, Pogostemonis 1-100 parts, Perilla 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-160 parts, Atractylodes macrocephala 1-120 parts, Gypsum fibrosum 1-100 parts, Fructus Crataegi 1-100 parts, Fructus Junci 1-100 parts, Fructus Hordei 1-100 parts, Lumbricus 1-100 parts, Radix et Rhizoma Veratri 1-100 parts, Herba Eupatorii Fortunei 1-100 parts, Semen Lepidii 1-100 parts and Semen Platycladi 1-100 parts.

The present application belongs to the technical field of plant growth regulators, and particularly relates to a compound for relieving high-temperature and drought combined stress of plants, a plant growth regulator and application, wherein the compound is formed by mixing 2-amino-3-methyl hexanoic acid and gibberellic acid at a mass ratio of 0.025-0.25:1. The present application uses 2-amino-3-methyl hexanoic acid and gibberellic acid to treat wheat at the initial filling stage and corn at the silking stage, so that yield reduction can be significantly relieved, the antioxidant enzyme activity can be improved, the high-temperature and drought resistance of wheat and corn can be enhanced, and then the yield reduction can be significantly relieved, and the yield loss caused by high-temperature and drought combined meteorological disasters can be reduced.

This invention discloses the application of ZBTB7A as a target in the preparation of products for the diagnosis or treatment of sepsis-associated encephalopathy (SAE), belonging to the field of biomedical technology. This invention confirms that ZBTB7A can serve as a diagnostic biomarker and therapeutic target for SAE, providing strong technical support for the early diagnosis and treatment of SAE. Clinical sample validation shows that the expression level of ZBTB7A in peripheral blood astrocyte-derived exosomes of SAE patients is significantly downregulated, enabling early, non-invasive auxiliary diagnosis of SAE with high clinical diagnostic efficacy. This invention clarifies that high expression of ZBTB7A can effectively inhibit the release of pro-inflammatory factors, reduce lipid peroxidation and iron overload, improve the structural and functional integrity of mitochondria, protect neuronal and synaptic structures, and significantly reverse cognitive impairment.